

Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis

Claudia F. Lucchinetti^{1*}, Wolfgang Brück^{2*}, Moses Rodriguez¹, Hans Lassmann³

¹Department of Neurology; Mayo Clinic Foundation; Rochester, Minnesota

²Institute of Neuropathology; Gottingen, Germany

³Institute of Neurology; Vienna, Austria

*These authors equally contributed to the content of the manuscript

Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system. The hallmark of its pathology is the demyelinated plaque with reactive glial scar formation. However, a detailed analysis of the patterns of demyelination, oligodendroglia cell pathology and the reaction of other tissue components suggests that the pathogenesis of myelin destruction in this disease may be heterogeneous. In this review we present a new classification scheme of lesional activity on the basis of the molecular composition of myelin degradation products in macrophages. When these criteria are used, different patterns of demyelination can be distinguished, including demyelination with relative preservation of oligodendrocytes, myelin destruction with concomitant and complete destruction of oligodendrocytes or primary destruction or disturbance of myelinating cells with secondary demyelination. Furthermore, in some cases a primary selective demyelination may be followed by secondary oligodendrocyte loss in the established lesions. Finally, some extraordinarily severe conditions may result in destructive lesions with loss of myelin, oligodendrocytes, axons and astrocytes. This heterogeneity of plaque pathology is discussed in the context of recent experimental models of inflammatory demyelination, which show that different immunological pathways may lead to the formation of demyelinated plaques that reveal the diverse structural aspects described above. Our data indicate, that the demyelinated plaques of multiple sclerosis may reflect a common pathological end point of a variety of different immunological mechanisms of myelin destruction in this disease.

Corresponding Author:

Professor Dr. Hans Lassmann, Institute of Neurology, University of Vienna, Schwarzschanerstrasse 17, Tel: (431) 40480257, Fax: (431) 403 4077, E-mail: hans.lassmann@univie.ac.at

Introduction

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system associated with focal destruction of the myelin sheath (14), and astrocytic scar formation. The pathological hallmark of MS is the white matter "plaque" which is widely scattered throughout the central nervous system (CNS), with a predilection for the optic nerves, brainstem, spinal cord and periventricular white matter. Despite extensive research, the etiology is unknown, the natural history is unpredictable, and currently there is no cure. Furthermore, because most neuropathological studies of MS have been based on examination of plaques during the late stages of the disease, there is minimal data regarding the features associated with the initiation and development of acute lesions. Recent studies suggest that patterns of inflammation, demyelination, and oligodendrocyte destruction may vary between individual MS patients, indicating that the pathogenetic mechanisms leading to demyelination may be fundamentally different in distinct subtypes of the disease.

Although it is generally accepted that the immune system contributes to the tissue destruction in MS, it is still unclear whether the immune response triggers the damage, or is a consequence of the disease process. In addition, there is debate over which components of the immune system are the key players in MS. Most investigators emphasize the role of CD4+ lymphocytes in inducing inflammation and demyelination, however the contribution of CD8+ cells, microglia/macrophages, astrocytes, cytokines, antibodies and complement are receiving increasing attention. Although most current concepts are based on the assumption that MS is caused by a single pathogenetic mechanism, there is extensive *in vivo* and *in vitro* data which indicates that many different toxic and immunological mechanisms may ultimately lead to the selective destruction of the myelin sheaths and oligodendrocytes. Such a pathogenetic diversity may also be reflected in the apparent multitude of susceptibility genes identified in recent genetic epidemiology studies on MS (16). Finally, recent serial MRI studies together with MRI spectroscopy (18,24,33,50) provide a better insight into the dynamic evolution of MS plaques and also suggest differences in the extent of inflammatory activity, blood brain barrier disturbance and

tissue damage between different clinical manifestations of the disease. These issues stress the need for a reevaluation of multiple sclerosis pathology, with a particular emphasis on defining the immunopathological events that occur in actively demyelinating lesions. Before doing so, it is essential to provide a precise definition of lesional activity.

Criteria For Defining Lesional Activity in MS Lesions

The criteria for identification of active lesions in the literature is controversial and often misleading. Table 1 summarizes existing criteria based upon myelin degradation products within macrophages and inflammatory activity.

The presence of gadolinium enhancement on MRI is used frequently by clinicians as a major criteria to define lesional activity, and is thought to reflect blood-brain-barrier (BBB) damage. Although this is considered to be one of the earliest changes observed in MS lesions, neuropathological and immunocytochemical studies reveal that BBB leakage can be found to variable degrees in every MS lesion, including inactive demyelinated plaques (7,84). These pathological findings appear to be in disagreement with recent MRI investigations that found Gd-DTPA leakage restricted to active MS lesions (33,49). This discrepancy may relate to the low sensitivity of MRI techniques in the detection of BBB dysfunction. Correlative studies revealed that Gd-enhancing MRI lesions corresponded to inflammatory infiltrations (primarily macrophages) accompanied by edema. Myelin destruction was not always present. Furthermore, the presence of BBB damage in other pathologic conditions without evidence of demyelination such as meningitis or encephalitis, implies that a non-specific T cell response alone is not sufficient to produce demyelination.

Attempts have also been made to define inflammatory activity within the lesion based upon the infiltration of the vessel walls and spread into CNS parenchyma by inflammatory cells (45,57), the upregulation of adhesion molecules (12,84,91), and MHC antigens (74), production of cytokines (29,80,92), and the definition of the activation stage of macrophages in the lesions (9). The results have been inconclusive since in a chronic inflammatory process such as MS the upregulation of immune associated molecules is rather a matter of quantity than quality and the spectrum of cytokine expression is broad.

Active plaques are often defined by the presence of cholesterol esters and neutral lipids in macrophages that can be stained by lipophilic dyes such as oil red O or sudan II (54,55,74). Although this is a suitable technique easily applied to fresh or formaldehyde fixed tissue, this sudanophilic stage of myelin degradation may persist for several months after the destruction of the myelin sheath (18,45). Therefore these observations may not reflect accurately the early stages of disease evolution. A better

definition of demyelinating activity within a plaque can be obtained by studying the structural profile and chemical composition of myelin degradation products within macrophages (27,36,40,45,78) and examining the expression of inflammatory macrophage activation antigens in the lesions (9,56). The time sequence of myelin degradation in macrophages found in monophasic experimental and human lesions has been studied (10,38). Minor myelin proteins such as myelin oligodendrocyte glycoprotein (MOG) or myelin associated glycoprotein (MAG) are rapidly degraded within macrophages within 1-2 days after phagocytosis. In contrast, major myelin proteins such as myelin basic protein (MBP) and proteolipid protein (PLP) may persist in macrophages for 6-10 days. In later stages, the macrophages contain sudanophilic and PAS-positive "granular lipids" that may persist in the lesion up to several months (45).

A recent study provided evidence for a differentiated pattern of macrophage activation in MS lesions obtained during the early course of the disease (9). In this study, different patterns of macrophage activation and differentiation in MS lesions were identified by using a panel of antibodies that recognized formalin-resistant macrophage-differentiation antigens. These patterns were then correlated with the stage of demyelinating activity as detected by the presence of myelin degradation products. The overall number of macrophages is highest in lesions with ongoing active demyelination as shown by using pan-macrophage markers such as Ki-M1P. A correlation was also found between the expression of macrophage activation antigens and the stage of demyelinating activity. The acute stage inflammatory markers MRP14 and 27E10 were selectively expressed in early (MRP14) or early and late active (27E10) lesions. In contrast, the chronic stage inflammatory macrophage marker (25F9), showed increasing expression with decreasing lesional activity. These findings demonstrated a sequential expression of macrophage activation antigens in MS lesions, thus providing parameters for defining the activity of MS plaques. Table 2 illustrates one current classification scheme to define lesional activity on the basis of myelin degradation products within macrophages, and macrophage activation markers. Although there is no generally accepted definition of MS plaque activity in the literature, this classification scheme provides a more uniform approach for future pathogenetic studies.

Timing and Target of the Inflammatory Response

Controversy surrounds the nature of the initial pathologic changes in MS. Although chronic persistent inflammation in the CNS is considered one of the most characteristic features of MS pathology, it remains unclear whether this inflammation is a primary or secondary phenomenon in lesion evolution.

CRITERIA FOR IDENTIFICATION OF ACTIVE LESIONS IN MULTIPLE SCLEROSIS

Myelin Degradation Products in Macrophages

Myelin balls/myelin fragments	<i>Seitelberger '60 ;Lumsden '70; Allen '90</i>
Cholesterol esters (ORO+)	<i>Seitelberger '60; Lumsden '70; Guseo and Jellinger '75; Li '93; Sanders '93</i>
Neutral lipids (PAS+)	<i>Adams '77</i>
Degraded MBP	<i>Lassmann '83; Prineas '85, '93, '93; Yao '94</i>
MOG/MAG (Early Active)	<i>Ozawa '94; Bruck'94</i>
MBP/PLP (Late Active)	<i>Ozawa '94; Bruck'94</i>

Macrophage Activation Markers

HLA-DR expression	<i>Traugott '83; Hayes '87; Li '93; Sanders '93</i>
MRP 14/27E10	<i>Bruck '95</i>

Hypercellularity of Plaque

Lumsden '70; Prineas '75; Guseo and Jellinger '75; Adams '77; Raine '81; Li '93; Sanders '93

Inflammatory Activity

Increased lymphocytes (T4, T8, T11)	<i>Traugott '83</i>
Upregulation of TNF- α /lymphotoxin	<i>Selmaj '91</i>
Cytokine upregulation	<i>Canella '95; Brosnan '95</i>
Adhesion molecule expression	<i>Sobel '90; Washington '94; Canella '95</i>
Fibronectin upregulation	<i>Sobel '89</i>

Table 1. ORO+: Oil red O positive, PAS+: Periodic acid Schiff positive reaction, MBP: Myelin basic protein, PLP: Proteolipid protein, MAG: Myelin-associated glycoprotein, MOG: Myelin oligodendrocyte glycoprotein

Most investigators suggest that the perivascular lymphocytic reaction initiates the demyelinating process (64). This would imply that immunologically active cells enter the CNS via activated endothelium and myelin would be destroyed either as a non-specific reaction by the release of lymphokines, or by antigen-specific mechanisms. There are several lines of evidence in support of the primary nature of the inflammatory process in MS. In experimental allergic encephalomyelitis (EAE), lymphocyte adherence to postcapillary venules with subsequent migration across the endothelium into the perivascular spaces and CNS parenchyma precedes demyelination (35,65). Perivascular inflammatory infiltrates are typically present in MS lesions in areas of active myelin breakdown. The inflammatory reaction in active MS lesions is associated with local upregulation of immunoregulatory molecules (histocompatibility antigens, cytokines, adhesion molecules,

chemokines), suggesting a contributing role for the inflammatory response in the disease. Immunocytochemical studies demonstrate the leakage of immunoglobulins and complement from capillaries and venules at the edges of active plaques, with evidence of damage to the vessel walls (21). Serial MRI studies reveal that clinical MS exacerbations are generally associated with focal BBB damage (24,50).

Although there is some evidence supporting a primary inflammatory attack on myelin, several key points are worth noting. Neuropathologic studies reveal that inflammatory cells and specifically T cells are not always present in areas of active demyelination (19,26,72). An ultrastructural study of 11 stereotactic brain biopsy specimens pathologically consistent with MS revealed evidence of myelin degeneration outside areas of maximal inflammation or macrophage infiltration suggesting that demyelina-

CLASSIFICATION OF DEMYELINATING ACTIVITY IN MS LESIONS ON THE BASIS OF MYELIN DEGRADATION PRODUCTS AND MACROPHAGE ACTIVATION

Stage	MOG	PLP	LFB	PAS	Vacuoles	Macrophage marker	Remyel
Early active	+++	++	++	-	-	MRP14	-
Late active	+	+++	++	-	-	27E10	-
Inactive	-	-	-	+/-	+/-	-	-
Early remyel	-	+/-	+/-	+	+	-	++
Late remyel	-	-	-	+/-	+/-	-	+++

Table 2. Staging is based on the presence of immunocytochemical or histochemical reactivity of macrophage degradation products and macrophage activation antigens in the lesions. MOG: Myelin oligodendrocyte glycoprotein; PLP: Proteolipid protein; LFB: Luxol fast blue; PAS: periodic acid Schiff reaction; Vacuoles: empty vacuoles (neutral lipids).

tion may have preceded inflammation (72). Although macrophages contained myelin debris within their cytoplasm, this observation could be interpreted as a consequence rather than the cause of myelin degradation, since similar patterns of macrophage activation are observed in other conditions not associated with myelin destruction. In addition, CT and MRI enhancement correlate with extensive macrophage infiltration (53), not lymphocyte invasion. The upregulation of MHC class II expression in active lesions located on pericytes, perivascular macrophages, microglia, and astrocytes (5,28,39,87) is not restricted to immune-mediated conditions. Other diseases not linked to T cell dysfunction such as trauma, infarcts, and neurodegenerative diseases (Alzheimer's disease), are also associated with class II MHC expression (48). Finally, silent plaques lacking a lymphocytic infiltrate can also express abundant class II on macrophages (66).

Ultrastructural Patterns of Myelin Destruction in MS

Most of our knowledge about MS neuropathology is based upon the study of the late chronic MS lesion characterized by a sharply demarcated area where myelin sheaths are selectively destroyed with relative axonal preservation and dense glial scar formation. In addition to these old sclerotic plaques, there may be active lesions with ongoing myelin destruction. Many different theories have been proposed to explain the process of demyelination in MS. Babinski (4) first described the interaction of debris containing cells with the demyelinating fiber and emphasized the central role of leukocytes in myelin destruction. Marburg (46), on the other hand, described that lysis of myelin is followed by the infiltration of phagocytic cells. He postulated a pathogenetic role for humoral myelinotoxic factors. Based upon ultrastructural studies, several patterns of

demyelination have been described:

a) *Receptor-mediated phagocytosis of myelin ("pinocytosis vermiformis")*: In this pattern an interaction of "coated pits and vesicles" on macrophages with myelin sheaths is found (62). Macrophages are thought to react with opsonized myelin (52,58) through Fc and complement receptors which are expressed in high density on the macrophage cell surface in active lesions (89). Myelin is then ingested by macrophages through vesicles or tubular channels. This view is supported by the demonstration of IgG deposition at the sites of macrophage/myelin interactions (61).

b) *Myelin stripping*: In this pattern, lymphocytes and macrophages invade myelin sheaths and can be found either between myelin lamellae or between the myelin sheath and axon. Disorganization or vesicular dissolution of myelin is present in the vicinity of the inflammatory cells. Although this is a common pattern seen in some EAE models, it appears to be relatively rare in MS and is found mainly in lesions of acute MS with prominent inflammatory infiltrates (36).

c) *Vesicular disruption of myelin sheaths*: Vesicular transformation of parts of the sheaths or even whole myelin has been found mainly in acute MS cases characterized by very severe and destructive lesions (25,36,39). However, a minor degree has also been described in chronic active MS plaques (34,45). This is a prominent pattern in experimental models of demyelination in which the lesions are mediated by antibody and complement (37). Although it is clear from experimental studies that this pattern of demyelination may occur in vivo, in human autopsy tissue this process may be exaggerated by post mortem autolysis (58).

d) *Dying back oligodendroglialopathy*: The hallmark of this pattern is characterized by pathological alter-

ations in the most distal extension of oligodendroglia cell processes. It was initially described in a model of toxic oligodendroglialopathy and demyelination (44) and more recently also reported as a feature of brain biopsies obtained during the early phases of the disease (72,73). This pattern of oligodendrocyte damage has been reported in virus-induced models of demyelination (68). Similar alterations have been observed in MAG deficient mice (unpublished observations). The changes of dying back oligodendroglialopathy may reflect impairment of oligodendrocyte metabolism in MS lesions since myelin gene expression in oligodendrocytes may be downregulated in the face of viral infection, inflammation, as well as in some MS cases (30,32,71). It is not certain whether these alterations invariably lead to oligodendrocyte destruction.

Unfortunately, these ultrastructural studies have been based on very small numbers of cases, and do not confirm a common mechanism of myelin destruction for all patients. Furthermore, these studies do not resolve the ongoing debate as to whether the myelin sheath or the oligodendrocyte is the primary target of the immune-mediated injury in MS.

Fate of the Oligodendrocyte

In cases of typical chronic MS, most investigators agree that the oligodendrocytes are largely absent from the lesion (36,45,58,72). The matter is less clear with regard to the fate of the oligodendrocyte in early stages of multiple sclerosis. Light microscopic, electron microscopic, and immunocytochemical studies have reported a variable degree of oligodendrocyte preservation in actively demyelinating lesions (36,58,67). Prineas (58,59,63) immunocytochemically examined fresh CNS lesions of patients with early MS and observed a striking loss of oligodendrocytes during active disease, followed by recruitment of large numbers of undifferentiated oligodendrocyte progenitors which are thought to repopulate the plaque. The final number of oligodendrocytes within a lesion would be dependent upon the availability of oligodendrocyte progenitor cells. Raine et al (67) and Selmaj (79,81) on the other hand described very high numbers of oligodendrocytes in early active lesions, however these cells were subsequently destroyed with disease progression. The authors suggested that oligodendrocytes survive the initial attack, but are later destroyed via additional immune-mediated mechanisms. Rodriguez (72,73) proposed that oligodendrocytes may be morphologically preserved in the acute lesion, but these cells do not function properly based on the alteration observed in the inner glial loops, the most distal extension of the oligodendroglial membrane. Therefore, the luxury function of these cells (i.e. myelination) may be disrupted without death to these cells. Lassmann et al (36) proposed that the degree of oligodendrocyte pathology may be

different between early and late stages of MS as well as between different patients.

In order to draw meaningful conclusions about the fate of the oligodendrocyte in a radially expanding MS lesion, it is essential to correlate oligodendrocyte numbers with stages of myelin degradation products in macrophages. However, previous neuropathological studies have been limited due to very small number of suitable cases and lesions, the difficulty in identifying oligodendrocytes within tissue sections, and the use of not well defined criteria of lesional activity. Several studies relied upon indirect criteria for oligodendrocyte identification such as the presence of cells with typical oligodendrocyte morphology, which were not stained by macrophage/microglia markers (59), or round cells that were larger than leukocytes (94). Furthermore, prior immunocytochemical markers used in MS tissue stained myelin antigens expressed in oligodendrocytes only at the peak of myelination/remyelination (58,62,63).

Recently developed techniques have better allowed the pathology of oligodendrocytes and patterns of oligodendrocyte death to be systematically studied in actively demyelinating MS lesions (10,56). We identified oligodendrocytes using two markers; the presence of proteolipid protein (PLP) mRNA within the cells, and the expression of myelin oligodendrocyte glycoprotein (MOG) on their surface. *In situ* hybridization for PLP mRNA is an early marker of oligodendrocyte differentiation and allows identification of oligodendrocytes engaged in myelin maintenance or synthesis (6,15,31). MOG is a protein that appears on the surface of oligodendrocytes and myelin late during myelination (47). In myelinated and demyelinated lesions, this protein is preserved on the surface of the oligodendrocyte and can be used to identify terminally differentiated oligodendrocytes within MS plaques. These markers were combined with DNA fragmentation in tissue sections (22,75) to identify cells that were degenerating within active MS lesions.

The MS material included in the study of Ozawa (56) included paraffin embedded biopsy and autopsy tissue from 28 cases with clinically and/or autopsy proven multiple sclerosis. The cases were grouped into three categories:

(i) *Acute multiple sclerosis*: These cases (n=9) were defined according to Marburg's criteria (46) and were characterized clinically by a severe relentlessly progressive or relapsing neurological disease leading to death within one year of onset.

(ii) *Early multiple sclerosis*: These specimens (n=6) consisted of stereotactic biopsies from patients during the first or second bout of the disease (11 days-7.5 months after disease onset). Patients were followed for an additional 2-7 years.

(iii) *Late multiple sclerosis*: This group (n=12) consisted of patients with chronic relapsing or chronic progressive disease for 1-21 years.




Figure 1. Oligodendrocyte preservation in MS. **A.** Early active MS lesion with macrophages containing MOG-reactive debris (arrows). Numerous MOG-positive oligodendrocytes (arrowheads) are present in the zone of active demyelination (immunocytochemistry for MOG). **B.** A large, activated oligodendrocyte with MOG at its surface (immunocytochemistry for MOG). **C.** Center of demyelinated plaque. Several small oligodendrocytes are present (immunocytochemistry for MOG). **D.** Center of a demyelinated plaque without remyelination. Many oligodendrocytes contain PLP mRNA (in situ hybridization for PLP mRNA (black) and immunocytochemistry for PLP protein (red)). **E.** Remyelinated lesion with MOG-positive oligodendrocytes (arrowheads) immunocytochemistry for MOG). **F.** Remyelinated shadow plaque with numerous oligodendrocytes that contain PLP mRNA (in situ hybridization for PLP mRNA (black) and immunocytochemistry for PLP protein (red)).

A parallel study by Brück et al. (10) focused more specifically on the pathology of early MS seen in biopsies taken during the first or second attack of the

disease. A total of thirty-six regions were examined and classified with respect to demyelinating activity based upon the profile of myelin degradation prod-




Figure 2. Active demyelination associated with oligodendrocyte loss in MS. **A.** Oligodendrocyte loss in an incompletely demyelinated plaque (b) compared to periplaque white matter (a) (in situ hybridization for PLP mRNA (black) and immunocytochemistry for PLP protein (red)). **B.** High power magnification of the plaque in A shows striking loss of oligodendrocytes (in situ hybridization for PLP mRNA (black) and immunocytochemistry for PLP protein (red)). **C.** Rare oligodendrocyte present within the actively demyelinated plaque (arrow; immunocytochemistry for MOG). **D.** Extensive macrophage infiltration throughout the lesion (immunocytochemistry for panmacrophage marker Ki-M1P). **E.** High power magnification of extensive macrophage infiltration (immunocytochemistry for Ki-M1P). **F.** MRP14 expression in macrophages from this early active MS lesion (immunocytochemistry for MRP14).

ucts within the cytoplasm of macrophages as summarized in Table 2.

The pattern of demyelination in all three categories (acute, early, late) was characterized by confluent plaques, and the inflammatory reaction was dominated by T lymphocytes and macrophages. A significant increase in the number of immunoglobulin producing plasma cells was present in inflammatory infiltrates from late chronic MS lesions. During

early exacerbations of MS, selective demyelination was associated with almost complete preservation of oligodendrocytes and a high number of remyelinating lesions. In lesions occurring during late chronic MS, demyelination was accompanied by extensive destruction and loss of oligodendrocytes. Remyelination was sparse in these cases. In Marburg's type of acute MS, demyelination was associated with extensive destruction of oligodendro-




Figure 3. Gradient of oligodendrocyte loss in MS. **A.** Progressive reduction of oligodendrocytes in a completely demyelinated plaque (b) compared to periplaque white matter (a) (in situ hybridization for PLP mRNA (black) and immunocytochemistry for PLP protein (red)). **B.** Center of demyelinated plaque with near complete loss of oligodendrocytes (in situ hybridization for PLP mRNA (black) and immunocytochemistry for PLP protein (red)). **C.** Early active edge of this lesion containing MOG-reactive debris (arrow; immunocytochemistry for MOG). **D.** Zone of numerous large activated MOG-positive oligodendrocytes near plaque edge (immunocytochemistry for MOG). **E.** Center of demyelinated plaque with few small MOG-positive oligodendrocytes (immunocytochemistry for MOG).

cytes, astrocytes and axons, however a considerable number of oligodendrocytes were preserved and capable of remyelination. This data suggested that in the majority of acute and early MS lesions, oligodendrocytes were largely preserved. However, in late chronic lesions there was a selective destruction of oligodendrocytes associated with the demyelination. The high number of plasma cells found in the CNS of patients with late chronic MS may indicate a pathogenetic role of antibodies in demyelination and oligodendroglial destruction, or may represent an attempt of these antibodies to promote repair (69). There were however exceptions to the general rule, with two out of seven early multiple sclerosis cases demonstrating a dramatic loss of oligodendrocytes, and three out of thirteen late chronic MS cases revealing lesions with considerable oligodendrocyte preservation. Loss or preservation of oligodendro-

cytes did not depend as much on the stage of lesion formation as suggested by previous studies (59,60,63), but rather was a characteristic feature, similar in all lesions or lesioned areas of a given patient. This suggested that at a given time during lesion evolution, the pathogenesis of the demyelinating process is similar in different brain regions. Furthermore, in the one patient who underwent sequential biopsies during the early phase of the disease, the numbers of oligodendrocytes within the different lesions were similar. These findings suggested that the pathogenesis of MS may vary in different patients and may change with chronicity of the disease process.

Patterns of cell death were also analyzed using DNA-fragmentation in degenerating cells (56). Extensive oligodendrocyte death was found at the borders of active lesions in chronic cases. Typically,




Figure 4. Destructive acute MS lesion. **A.** Well demarcated demyelinated plaque with massive macrophage infiltration and edema; (a) periplaque white matter; (b) plaque center (immunocytochemistry for MOG (blue)). **B.** Extensive axonal loss in this lesion associated with axonal changes (Bielschowsky). **C.** Demyelinated plaque edge and center. Some oligodendrocytes survive the destructive process (in situ hybridization for PLP mRNA (black) and immunocytochemistry for PLP protein (red)). **D.** Higher magnification of C illustrating several preserved oligodendrocytes (arrows). **E.** Actively demyelinating lesion with numerous degenerating cells (black nuclei) that show nuclear DNA fragmentation (arrows; double staining with immunocytochemistry for PLP protein (red)). **F.** Astrocyte loss in acute MS (GFAP).

dying oligodendrocytes were found in the area of active myelin destruction. These findings were interpreted as evidence for oligodendrocytes dying concomitantly with myelin sheaths, or secondarily to myelin destruction. In this limited study, both apoptosis and necrosis patterns of cell death were found. Using similar techniques, we have collected three cases of primary progressive chronic MS which

demonstrated a fundamentally different pattern of cell death. In these cases, oligodendrocytes were predominantly destroyed in a thin rim of normal appearing white matter immediately adjacent to the actively demyelinating plaque edge. This pattern suggests that in some primary progressive MS lesions, demyelination may occur secondary to oligodendroglia damage. These observations need to be con-




Figure 5. Pattern of cell death in a case of chronic progressive MS. **A.** DNA fragmentation is present in a small area in the periplaque white matter adjacent to the actively demyelinating plaque border (arrows); black nuclei are cells with DNA fragmentation, double-staining with immunocytochemistry for MOG protein (red). **B.** Higher magnification of A shows that degenerating cells with DNA fragmentation (arrows) are located in the periplaque white matter.

firmed in a larger series, however they suggest that the pathogenesis of primary progressive MS may be different from the pathogenesis of relapsing or secondarily progressive disease.

Since the original studies by Ozawa (56) and Brück (10) were restricted to a small total number of cases, we have initiated a similar study in a very large series of MS cases collected at the Mayo Clinic (n=44), the Institute of Neuropathology in Göttingen (n=22), and the Institute of Neurology in Vienna (n=16). It is based on 82 cases in which brain biopsies from early bouts of the disease were available, 16 autopsy cases of acute MS (46) and 9 cases of chronic active MS. The goal of the study was to exclude that the high variability of oligodendrocyte pathology in the previous studies of Ozawa (56) and Brück (10) were due to sample bias. Demyelinating activity in the lesions was determined on the basis of myelin degradation products in macrophages and the presence of early macrophage activation markers, as summarized in Table 2. Our preliminary results indicate at least five distinct patterns of lesional pathology to be discriminated:

(I) Demyelination with no or only minor oligodendrocyte loss (Figure 1): As in all other MS lesions, myelin was completely lost in these plaques. Active myelin destruction at the lesional borders was associated with a variable but minor reduction (up to 30%) of oligodendrocytes. DNA fragmentation of oligodendrocytes was rare. Remyelination was rapid and complete.

(II) Demyelination with concomitant destruction and loss of oligodendrocytes (Figure 2): In these lesions, active demyelination was associated with extensive or complete loss of oligodendrocytes. In the area of active myelin destruction many cells with DNA fragmentation were present that expressed markers for oligodendrocytes (MOG, CNPase, or PLP mRNA). Morphological analysis of dying oligodendrocytes revealed that in some cases cell destruction was mediated by apoptosis, whereas in others, particularly those cases with a high plasma cell density, necrosis was dominant. Inactive plaques showed demyelination, extensive glial scarring, and limited remyelination.

(III) Primary demyelination with a gradient of oligodendrocyte loss towards the inactive plaque center (Figure 3): In these lesions, similar to the first pattern described above, oligodendrocyte density was high in the areas of active myelin breakdown. Yet towards the plaque center there was a progressive reduction of oligodendrocyte density and dying oligodendrocytes were frequently observed. Oligodendrocyte loss was mediated mainly through apoptosis, although in one case with high plasma cell density, necrosis was noted. The center of such plaques showed demyelination and glial scarring without remyelination.

(IV) Destructive plaques (Figure 4): These lesions were characterized by more extensive macrophage infiltration and a more pronounced

state of activation as compared to the previously reported patterns. Widespread demyelination paralleled destruction of oligodendrocytes, axons, and astrocytes. However, as described before, (56), oligodendrocytes were partly preserved even in the most destructive areas of these lesions. This pattern of demyelination was particularly prominent in cases of Marburg's type of acute multiple sclerosis.

(V) Demyelinating plaques with oligodendrocyte destruction in the periplaque white matter (Figure 5): These plaques revealed demyelination, glial scarring, and complete loss of oligodendrocytes. No signs of remyelination were present. Even in the areas of active myelin destruction, oligodendrocytes were sparse and only few cells showed DNA fragmentation. Yet, dying cells were abundant in a small zone of the periplaque white matter. This pattern of demyelination was found in three autopsy cases of primary progressive MS and in rare instances in biopsy specimens from early bouts of the disease.

Can these patterns of MS pathology be explained on the basis of the stage of demyelinating activity, the severity of a single pathogenetic mechanism, or the possibility that multiple pathogenetic mechanisms may be acting in parallel within the same lesion?

Timing of the lesion: If MS is a disease caused by a single pathogenetic mechanism, one would predict that previous observations on the high variability of oligodendrocyte damage are secondary to a stage-specific phenomenon. However, our data demonstrated no correlation between the observed pattern of pathology and the stage of demyelinating activity within the lesion based upon macrophage activation or myelin degradation products. Furthermore, similar to Brück et al's (10) initial observation in a smaller series, our data confirmed that oligodendrocyte loss or survival was similar in all parts of a lesion from a given patient.

Severity of a single pathogenetic mechanism: Obviously the severity of the pathogenetic process in a given lesion will determine its structural outcome. In mild forms of autoimmune encephalomyelitis, selective demyelination and rapid remyelination occur, which in more severe instances leads to unselective tissue damage, similar to that described in the destructive lesions (36). Yet this alone cannot explain why in some MS lesions oligodendrocytes are destroyed completely and selectively, whereas in others these cells are partly preserved, even in the most destructive areas. Furthermore, the preferential pattern of oligodendrocyte destruction by either apoptosis or necrosis, as well as oligodendrocyte death occurring either in areas of demyelination or in the periplaque white matter, are not possible to simply relate to differences in the severity of a single pathogenetic mechanism.

Multiple mechanisms acting in parallel: In at least two cases characterized by a progressive loss of oligodendrocytes toward the plaque center, oligodendro-

cyte death occurred via either apoptosis or necrosis and seemed independent from the demyelination and oligodendrocyte destruction occurring at the plaque border. This raises the possibility that several pathogenetic mechanisms were acting in parallel within the same lesion. However, in the majority of lesions examined, individual patients followed distinct pathogenetic pathways of lesion formation.

Since the different patterns of lesional pathology in different MS cases cannot be explained alone on the basis of timing and severity of a single pathogenetic pathway, our data suggest that the primary target of the demyelinating process may vary between individual patients and thus may reflect distinct immunopathogenetic mechanisms operating in different MS patients.

Multiple Different Pathogenetic Pathways of Demyelination May Lead to Different Lesion Subtypes

What pathogenetic mechanisms could be responsible for these observed patterns of demyelination and oligodendrocyte destruction? Studies of experimental animal models of demyelination may provide important clues on the potential pathogenetic mechanisms for multiple sclerosis. Demyelination in animals may be produced immunologically by the injection of myelin components or transfer of CNS-specific T cells, by viruses from various families (picornaviruses, coronaviruses, herpes viruses, retroviruses) and by toxins (lysolecithin, ethidium bromide, cuprizone). It is possible that the differing patterns of oligodendroglial pathology and demyelination observed in the various patients have correlates in the animal models in which the inciting event and immunopathogenetic mechanisms are better understood. Considering the spectrum of different mechanisms leading to immune mediated demyelination in experimental models *in vivo* and *in vitro*, the different lesional patterns, as described above, is not unexpected.

Demyelination with relative sparing of oligodendrocytes and rapid remyelination is the expected pattern when the pathogenetic process is primarily directed against the myelin sheath. This could be accomplished by a bystander reaction, mediated by immunotoxins that are liberated in the course of the T-cell mediated inflammation. A variety of immunotoxins, including oxygen radicals (23), tumor-necrosis factor alpha (82), lymphotoxin (80), complement (77) or perforin (76) lyse preferentially myelin and oligodendrocytes *in vitro*. However, when overexaggerated these same toxins will lead to unselective tissue damage, similar to that observed in destructive lesions. Thus, in chronic models of T-cell mediated autoimmune encephalomyelitis, demyelination occurs which is followed by rapid and complete remyelination (67). Only in severe conditions, as for instance in EAE in transgenic animals that overex-

press TNF- α , persistent lesions are present that are associated with severe and unselective tissue damage.

Another possible mechanism is myelin destruction by demyelinating antibodies that act in synergy with a T-cell mediated encephalitogenic response (41). At present the best characterized target antigen for demyelinating antibodies is myelin oligodendrocyte glycoprotein (MOG). MOG is strongly expressed on the extracellular surface of myelin sheaths and peripheral oligodendrocyte processes, but only in low density on the oligodendrocyte pericaryon (11). Demyelination induced in EAE animals by anti-MOG antibodies is associated with a variable extent of oligodendrocyte necrosis. Since MOG is not expressed on progenitor cells, rapid recruitment of new oligodendrocytes and remyelination occurs. Repeated demyelinating episodes by this mechanism lead to persistently demyelinated lesions, most likely due to progressive destruction of both mature and immature oligodendrocytes (42). "Receptor-mediated phagocytosis" of myelin and capping of surface immunoglobulin G on macrophages engaged in myelin breakdown as described by Prineas and Graham (61) and Prineas (58) in multiple sclerosis lesions indeed argues in favor of an antibody mediated mechanism. Furthermore, the presence of plasma cells secreting anti-MOG antibodies has been shown in the CSF of some MS patients (85).

Demyelinating lesions with complete loss of oligodendrocytes and lack of remyelination most likely are due to a pathogenetic mechanism which not only eliminates mature oligodendrocytes but also effectively destroys the progenitor pool. Although this may be achieved in lesions with repeated de- and remyelination occurring in the chronic stages of MS (43,60), such a mechanism is unlikely to operate in similar lesions seen in initial exacerbations of the disease. In the latter, there may either be a functional defect of oligodendrocyte precursor cells, or the immune response may be directed against an antigen present in mature as well as immature oligodendrocytes. Candidate antigens could be early differentiation markers of oligodendrocytes such as galactocerebroside or sulfatides, or a novel antigen peptide expressed following virus infection. In the Theiler's virus model of multiple sclerosis induced by a picornavirus, various target cells such as oligodendrocytes, astrocytes and macrophages are infected. An immune response destroys oligodendrocytes and prevents subsequent remyelination as a result of an immune response attempting to clear persistent infection (68).

Cases presenting with a *gradient of oligodendrocyte loss from the active lesion edge into the plaque center* indicate that in some multiple sclerosis patients "stressed" oligodendrocytes, while attempting remyelination in the hostile environment of an active plaque, may become a target of destruction. Such a mechanism has been suggested by Selmaj et al

(81) who described the intimate contact between gamma/delta T lymphocytes with reactive oligodendrocytes in the plaques. A prominent and oligoclonal gamma/delta T-cell response has been observed in some active MS lesions (93). These T cells preferentially lyse oligodendrocytes in vitro (20), possibly by the recognition of stress proteins. Within MS lesions stress proteins such as hsp65 (79) or alpha B crystallin (90) are upregulated in oligodendrocytes, apparently at the time when they begin remyelination. Thus, in cases with a gradient of oligodendroglia cell loss, these cells may have escaped the primary demyelinating insult, but may then be destroyed by a second immune reaction against stress proteins.

Alternatively, a gradient loss of oligodendrocytes could also be explained by a lack of sufficient growth factors that allow oligodendrocyte progenitor cells to survive in the plaque environment and to differentiate into mature myelinating cells. In line with this concept, remyelinating lesions in EAE can be augmented by exogenous application of insulin like growth factor (IGF). Furthermore, withdrawal of growth factors may lead to apoptosis.

Lesions with oligodendrocyte death occurring in the periplaque white matter outside the zone of active myelin degeneration suggests that in a subgroup of multiple sclerosis patients, primary oligodendrocyte destruction may lead to secondary demyelination. One possible mechanism of primary oligodendrocyte damage could be a persistent viral infection in this cell population. A variety of different virus-induced experimental models of demyelination are available (68) which show impairment of metabolic functions of oligodendrocytes (32,71). In addition, toxins which interfere with the function of oligodendrocytes could result in this pattern of pathology (44). Several studies have demonstrated the presence of virus antigens or respective nucleotide sequences in multiple sclerosis lesions (3,13). Although there has been no convincing or repeated demonstration of a single virus in MS tissue, it still remains open whether a group of persistent virus infections may play a role in subsets of MS patients. A primary damage of oligodendrocytes as seen in the lesions of several patients in our series may further support this notion. Yet primary oligodendrocyte damage may also occur in immune-mediated conditions. A dysregulation of microglia / macrophages could theoretically lead to oligodendrocyte apoptosis and demyelination, via free oxygen radicals (23) or TNF-alpha mediated injury. In vitro, TNF-alpha produces oligodendrocyte destruction via apoptosis (82,51), although this toxicity occurs only at very high concentrations which may not be physiologic.

In conclusion, our studies on the patterns of demyelination and oligodendrocyte destruction in MS lesions underscore the pathologic heterogeneity observed in MS. These observations challenge the existing scientific dogma that MS is a disease caused

by a single pathogenetic mechanism, and rather suggest that the pathogenetic mechanisms leading to demyelination may be fundamentally distinct in different groups of MS patients. This hypothesis may in part explain the variable clinical picture with respect to the neurologic symptoms, natural history, and degree of disability seen in this disease. Furthermore, genetic studies support the theory that the expression of the disease is under polygenic control. It may be that combinations of different susceptibility genes may ultimately dictate the patient's immunopathogenetic response to the inciting injury, and account for specific subtypes of this complex disease. Whether there is only one versus multiple inciting events cannot be determined. These findings may have implications with respect to the design of future therapeutic strategies in MS. We currently rely upon large placebo-controlled double-blind studies to determine whether a particular therapy is efficacious in patients. This approach does not take into account that a therapy which may be useful in one group of patients may be ineffective or possibly deleterious in another. In addition, the existing criteria used to select patients suitable for a clinical trial may not accurately reflect the specific pathogenetic substrate of the disease. The correlation of the patterns we have observed with clinical or paraclinical parameters may ultimately lead to the development of novel therapeutic strategies designed to target different subtypes of multiple sclerosis.

Acknowledgement

This study was partly funded by the Mayo Foundation Scholarship program, the Austrian Science Foundation Project P 10608 MED, and grants from the Gemeinnutzige Hertie-Stiftung.

References

1. Adams CW (1977) Pathology of multiple sclerosis: progression of the lesion. *Brit Med Bull* 33:15-20
2. Allen I (1990) Pathology of multiple sclerosis. In *McAlpine's Multiple Sclerosis*, W.B. Matthews (ed), pp 341-378, Churchill Livingstone: Edinburgh
3. Allen I, Brankin B (1993) Pathogenesis of multiple sclerosis: the immune diathesis and the role of virus. *J Neuropathol Exp Neurol* 52:95-105
4. Babinski J (1885) Recherches sur l'anatomie pathologique de la sclerose en plaque et etude comparative des diverses varietes de la sclerose de la moelle. *Arch Physiol (Paris)* 5-6:186-207
5. Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BO (1994) Detection of MHC class II on macrophages and microglia but not astrocytes and endothelia in active multiple sclerosis lesions. *J Neuroimmunol* 51:135-146
6. Breitschopf H, Suchanek G, Gould RM, Coleman DR, Lassmann H (1992) In situ hybridization with digoxigenin-labelled probes: sensitive and reliable detection method applied to myelinating rat brain. *Acta Neuropathol (Berl)* 84:581-587
7. Broman Y (1964) Blood brain barrier damage in multiple sclerosis plaques. *Am J Pathol* 137:575-584

8. Brosnan CF, Cannella B, Battistini L, Raine CS (1995) Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. *Neurology* 45:S16-S21
9. Brück W, Porada P, Poser S, Rieckmann, Hanefeld F, Kretzschmar H, Lassmann H (1995) Monocyte / macrophage differentiation in early multiple sclerosis lesions. *Ann Neurol* 38:788-796
10. Brück W, Schmied M, Suchanek G, Bruck Y, Breitschopf H, Poser S, Piddlesden S, Lassmann W (1994) Oligodendrocytes in the early course of multiple sclerosis. *Ann Neurol* 35:65-73
11. Brunner C, Lassmann H, Waehnelt ThV, Matthieu JM, Linington C (1989) Differential ultrastructural localization of myelin basic protein, myelin/oligodendrocyte glycoprotein and 2'3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. *J Neurochem* 52:296-304
12. Canella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. *Ann Neurol* 37:424-435
13. Challoner PB, Smith KT, Parker JD, Macleod DL, Coulter SN, Rose TM, Schultz ER, Bennett JL, Garber RL, Chang M, Schad PA, Stewart PA, Nowinski RC, Brown JP, Burmer GC (1995) Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. *Proc Natl Acad Sci USA* 92:7440-7444
14. Charcot JM (1868) Histologie de la sclerose en plaque. *Gaz Hopital (Paris)* 41:554-56
15. Coleman, Kreibich G, Frey AB, Sabatini DD (1982) Synthesis and incorporation of myelin polypeptides into CNS myelin. *J Cell Biol* 95:598-608
16. Compston DA, Keller WH, Robertson H, Saucer S, Wood NW (1995) Genes and susceptibility to multiple sclerosis. *Acta Neurol Scand* 161:43-51
17. Dal Canto MC, Rabinowitz SG (1982) Experimental models of virus-induced demyelination of the central nervous system. *Ann Neurol* 11:109-127
18. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDoanld WI (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis. *Brain* 117:49-58
19. Dawson JW (1916) The histology of disseminated sclerosis. *Trans Roy Soc Edinburgh* 5:517-740
20. Freedman MS, Ruijs TC, Selin LK, Antel JP (1991) Peripheral blood gamma/delta T cells lyse fresh human brain derived oligodendrocytes. *Ann Neurol* 30:794-800
21. Gay D, Esiri M (1991) Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytochemical study. *Brain* 114:557-572
22. Gold R, Schmied M, Rothe G, Zischler H, Breitschopf H, Wekerle H, Lassmann H (1993) Detection of DNA fragmentation in apoptosis: application of in situ nick translation to cell culture systems and tissue sections. *J Histochem Cytochem* 41:1023-30
23. Griot C, Vandeveld M, Richard A, Peterhans E, Stocker R (1990) Selective degeneration of oligodendrocytes mediated by reactive oxygen species. *Free Republic Res Commun* 11:181-193
24. Grossmann RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzales-Scarano F (1988) Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. *Radiology* 169:117-122
25. Guo YP, Gao SF (1983) Concentric sclerosis. In *Clinical and Experimental Neurology*, JH Tyrer, MJ Eadie (eds), Proc Australian Association of Neurologists Vol 19; pp 67-76, Adis Health Science Press, Sydney
26. Guseo A, Jellinger K (1975) The significance of perivascular infiltrations in multiple sclerosis. *J Neurol* 211:51-60
27. Hallpike JF, Adams CW, Bayliss OB (1970) Histochemistry of myelin. Loss of basic protein in early multiple sclerosis plaques. *Histochem J* 2:323-328
28. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL (1986) An immunocytochemical analysis of the cellular infiltrates in multiple sclerosis lesions. *Ann Neurol* 19(6):578-587
29. Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Tumor-necrosis factor identified in multiple sclerosis brain. *J Exp Med* 170:607-612
30. Itoyama Y, Sternberger NH, Webster HdeF, Quarles RH, Cohen SR, Richardson EP Jr (1980) Immunocytochemical observation on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. *Ann Neurol* 14:339-346
31. Jordan C, Friedrich V Jr, Dubois Dalcq ME (1989) In situ hybridization analysis of myelin gene transcripts in developing mouse spinal cord. *J Neurosci* 9:248-257
32. Jordan CA, Friedrich VL Jr, Godfraind C, Cardellechio CB, Holmes KV, Dubois-Dalcq M (1989) Expression of viral and myelin gene transcripts in a murine CNS demyelinating disease caused by a coronavirus. *Glia* 2:318-329
33. Kermod AG, Thompson AJ, Tofts B, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI (1990) Breakdown of the blood brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. *Brain* 113:1477-1489
34. Kirk J (1979) The fine structure of the CNS in multiple sclerosis. Vesicular demyelination in an acute case. *Neuropathol Appl Neurobiol* 5:289-294
35. Lampert PW, Carpenter S (1965) Electron microscope studies on the vascular permeability and the mechanisms of demyelination in experimental allergic encephalomyelitis. *J Neuropath Exp Neurol* 29:11-24
36. Lassmann H (1983) Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. *Schriftenr Neurol* 25:1-135
37. Lassmann H, Brunner C, Bradl M, Linington C (1988) Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determine size and structure of demyelinated lesions. *Acta Neuropathol (Berl)* 75:566-576
38. Lassmann H, Wisniewski HM (1979) Chronic relapsing experimental allergic encephalomyelitis: Morphological sequence of myelin degradation. *Brain Res* 169:357-368
39. Lee SC, Moore GR, Golensky G, Raine CS (1990) Multiple sclerosis: a role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. *J Neuropathol Exp Neurol* 49:122-136
40. Li H, Newcombe J, Groome NP, Cuzner ML (1993) Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques. *Neuropathol Appl Neurobiol* 19:214-223
41. Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against myelin/oligodendrocyte glycoprotein (MOG). *J Neuroimmunol* 17:61-69
42. Linington C, Engelhardt B, Kapocs G, Lassmann H (1992) Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalito-

- genic T-cells and demyelinating antibodies. *J Neuroimmunol* 40:219-224
43. Ludwin SK (1980) Chronic demyelination inhibits remyelination in the central nervous system. An analysis of contributing factors. *Lab Invest* 43:382-387
 44. Ludwin SK, Johnson ES (1981) Evidence of a "dying-back" gliopathy in demyelinating disease. *Ann Neurol* 9:301-305
 45. Lumsden CE (1970) The neuropathology of multiple sclerosis. In *Handbook of Clinical Neurology*, Vinken PI, Bruyn GW (eds), vol 9, pp.217-309, Elsevier: New York
 46. Marburg O (1906) Die sogenannte "akute Multiple Sklerose". *Jahrb Psychiatrie* 27:211-312
 47. Matthieu J-M, Amiguet P (1990) Myelin/oligodendrocyte glycoprotein expression during development in normal and myelin-deficient mice. *Dev Neurosci* 12:293-302
 48. McGeer RL, Itagaki S, Tago H, McGeer EG (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. *Neurosci Lett* 79:195-200
 49. McLean BN, Zeman AZ, Barnes D, Thompson EJ (1993) Patterns of blood brain barrier impairment and clinical features in multiple sclerosis. *J Neurol Neurosurg Psychiatr* 56:356-360
 50. Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, Barnes D, McDonald WI (1988) Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. *Brain* 111:927-939
 51. Mitrovic B, Martin FC, Charles AC, Ignarro LJ, Anton PA, Shanahan F, Merrill JE (1994) Neurtotransmitters and cytokines in CNS pathology. *Prog Brain Res* 103:319-330
 52. Moore GR, Raine CS (1988) Immunogold localization and analysis of IgG during immune-mediated demyelination. *Lab Invest* 59:641-648
 53. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M (1991) Histopathologic and MR and/or CT correlation in 37 cases at biopsy and 3 cases at autopsy. *Radiology* 180:467-474
 54. Newcombe J, Cuzner ML (1993) Organization and research applications of the U.K. Multiple Sclerosis Society tissue bank. *J Neurol Transm (Suppl)* 39:155-163
 55. Newcombe J, Li H, Cuzner ML (1994) Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. *Neuropathol Appl Neurobiol* 20:152-162
 56. Ozawa K, Suchanek G, Breitschopf H, Bruck W, Budka H, Jellinger K, Lassmann H (1994) Patterns of oligodendroglia pathology in multiple sclerosis. *Brain* 117:1311-1322
 57. Prineas J (1975) Pathology of the early lesion in multiple sclerosis. *Hum Pathol* 6:531-554
 58. Prineas JW (1985) The neuropathology of multiple sclerosis. In *Handbook of Clinical Neurology*, JC Koetsier (ed), Vol 47, pp 337-395, Elsevier Science
 59. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES (1993) Multiple sclerosis. remyelination of nascent lesions. *Ann Neurol* 33:137-151
 60. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES (1993) Multiple sclerosis. Pathology of recurrent lesions. *Brain* 116:681-693
 61. Prineas JW, Graham JS (1981) Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. *Ann Neurol* 10:149-158
 62. Prineas JW, Kwon EE, Cho ES, Sharer LR (1984) Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. *Ann NY Acad Sci* 436:11-332
 63. Prineas JW, Kwon EE, Goldenberg PZ, Ilyas AA, Quarles RH, Benjamin JA, Sprinkle TJ (1989) Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. *Lab Invest* 61:489-503
 64. Prineas JW, Raine CS (1976) Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions. *Neurology* 26:29-32
 65. Raine CS (1994) Multiple sclerosis: immune system molecule expression in the central nervous system. *J Neuropath Exp Neurol* 53:328-337
 66. Raine CS (1994) The Dale E McFarlin memorial lecture. The immunology of the multiple sclerosis lesion. *Ann Neurol* 36:S61-S72
 67. Raine CS, Scheinberg L, Waltz JM (1981) Multiple Sclerosis: Oligodendrocyte survival and proliferation in an active established lesion. *Lab Invest* 45:534-546
 68. Rodriguez M (1992) Central nervous system demyelination and remyelination in multiple sclerosis and viral models of disease. *J Neuroimmunol* 40:255-263
 69. Rodriguez M, Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. *Ann Neurol* 27:12-17
 70. Rodriguez M, Miller DJ (1994) Immune promotion of central nervous system remyelination. *Prog in Brain Res* 103:343-355
 71. Rodriguez M, Prayoonwiwat N, Howe C, Sanborn K (1994) Proteolipid protein gene expression in demyelination and remyelination of the central nervous system: a model for multiple sclerosis. *J Neuropath Exp Neurol* 53:136-1443
 72. Rodriguez M, Scheithauer B (1994) Ultrastructure of multiple sclerosis. *Ultrastructural Pathol* 18:3-13
 73. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ (1993) Oligodendrocyte injury is an early event in lesions of multiple sclerosis. *Mayo Clin Proc* 68:627-636
 74. Sanders V, Conrad AJ, Tourtellotte WW (1993) On classification of post-mortem multiple sclerosis plaques for neuroscientists. *J Neuroimmunol* 46:207-216
 75. Schmied M, Breitschopf H, Gold R, Zischler H, Rothe G, Wekerle H, Lassmann H (1993) Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. *Am J Pathol* 143:446-452
 76. Scolding NJ, Jones J, Compston DAS, Morgan BP (1990) Oligodendrocyte susceptibility to injury by T-cell perforin. *Immunology* 70:6-10
 77. Scolding NJ, Morgan BP, Houston A, Campbell AK, Linington C, Compston DAS (1989) Normal rat serum cytotoxicity against syngeneic oligodendrocytes complement activation and attack in the absence of anti-myelin antibodies. *J Neurol Sci* 89:289-300
 78. Seitelberger F (1960) Histochemistry of demyelinating diseases proper, including allergic encephalomyelitis and Pelizaeus Merzbacher's disease. In *Modern Scientific Aspects of Neurology*, Cumings JN (ed), Arnold: London, pp 146-187
 79. Selmaj K, Brosnan CF, Raine CS (1992) Expression of heat shock protein-65 by oligodendrocytes in vivo and in vitro: implications for multiple sclerosis. *Neurology* 42:795-800
 80. Selmaj K, Raine CS, Cannella B, Brosnan CF (1991) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. *J Clin Invest* 87:949-954

81. Selmaj KW, Brosnan CF, Raine CS (1991) Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. *Proc Natl Acad Sci (USA)* 88:6452-6456
82. Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. *Ann Neurol* 23:339-346
83. Sobel RA, Mitchell ME (1989) Fibronectin in multiple sclerosis lesions. *Am J Pathol* 135:161-168
84. Sobel RA, Mitchell ME, Fondren G (1990) Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. *Am J Pathol* 136:1309-1316
85. Sun J, Link H, Olsson T, Xiao BG, Anderson G, Ekre HP, Linington C, Diener P (1991) T and B cell responses to myelin oligodendroglia glycoprotein in multiple sclerosis. *J Immunol* 146:1490-1495
86. Tavolato B (1975) Immunoglobulin G distribution in multiple sclerosis brain. An immunofluorescence study. *J Neurol Sci* 24:1-11
87. Traugott U (1987) Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. *J Neuroimmunol* 16:283-302
88. Traugott U, Reinherz EL, Raine CS (1983) Distribution of T cell subsets and Ia-positive macrophages in lesions of different ages. *J Neuroimmunol* 4:201-221
89. Ulvestad E, Williams K, Vedeler C, Antel J, Nyland H, Mork S, Matre R (1994) Reactive microglia in multiple sclerosis lesions have increased expression of receptors for the Fc part of IgG. *J Neurol Sci* 121:125-131
90. Van Noort JM, van Sechel AC, Bajramovic J, El Ouagmiri M, Polman CH, Lassmann H, Ravid R (1995) A novel candidate autoantigen in multiple sclerosis: $\alpha\beta$ -crystallin, a small heat shock protein. *Nature* in press
91. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P (1994) Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. *Ann Neurol* 35:89-97
92. Woodroffe MN, Cuzner ML (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by nonradioactive in situ hybridization. *Cytokine* 5:583-588
93. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA (1992) Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. *Proc Natl Acad Sci USA* 89:4588-4592
94. Yao DL, Webster HdeF, Hudson LD, Brenner M, Liu DS, Escobar AI, Komoly S (1991) Concentric sclerosis (Balo); morphometric and in situ hybridization study of lesions in six patients. *Ann Neurol* 35:18-30